Which biopsy is best for hilar cancer? new study aims to find out
NCT ID NCT05993429
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares two ways to get tissue samples from a suspected hilar bile duct cancer: one using an endoscope with ultrasound guidance (EUS-FNA/B) and another using a scope to look directly into the bile ducts (ERCP with or without a special camera). Researchers will check which method is more accurate, safer, and more cost-effective. The study involves 200 adults with suspected hilar cholangiocarcinoma based on imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose the best biopsy method for diagnosing hilar bile duct cancer, improving accuracy and reducing complications.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve patient outcomes. Results may vary based on individual patient factors and expert judgment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOPSY, FINE-NEEDLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250063, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Web tool aims to empower rare cancer patients in genomic choices